iBio - Preclinical PD-1 Agonist Antibody Program - Ownership and Business Overview

Life ScienceCompany

iBio - Preclinical PD-1 Agonist Antibody Program Ownership

Who owns iBio - Preclinical PD-1 Agonist Antibody Program?

iBio - Preclinical PD-1 Agonist Antibody Program is owned by Otsuka Pharmaceutical. It was acquired on February 25, 2024.

iBio - Preclinical PD-1 Agonist Antibody Program Business Overview

Where is iBio - Preclinical PD-1 Agonist Antibody Program headquartered?

iBio - Preclinical PD-1 Agonist Antibody Program is headquartered in Bryan, Texas.

What sector is iBio - Preclinical PD-1 Agonist Antibody Program in?

iBio - Preclinical PD-1 Agonist Antibody Program is a life science company.

Life Science M&A Summary in 2024

Out of 60 sectors in the Mergr database, life science ranked 6 in number of deals in 2024. The largest life science acquisition in 2024 was Catalent - which was acquired by Novo Holdings A/S for $16.5B.

Join Mergr to view all 96 acquisitions of life science companies in 2024, including 7 acquisitions by private equity firms, and 89 by strategics.

iBio - Preclinical PD-1 Agonist Antibody Program

iBio - Preclinical PD-1 Agonist Antibody Program

Bryan, Texas 77807
United States,

iBio - Preclinical PD-1 Agonist Antibody Program is a pivotal checkpoint in the immune system, acting as a type of off switch that helps keep the cells from attacking other cells in the body. iBio's Preclinical PD-1 Agonist Antibody Program is based in Bryan, Texas.


Company Summary

SECTOR

Life Science

 Subscribe to unlock this and 202,409
investor and company profiles

Sign-up today to get full access

  • check  Unlimited Searches
  • check  Unlimited Profile Views
  • check  Build and Export Lists of
    • PE Backed Companies
    • Direct Investors & Acquirers
    • Advisors
    • Deals
    • & More
1 Week Free Trial Learn More

What's Mergr?

We built Mergr to save people the arduous and time-consuming process of tracking when companies are bought, sold, and who currently owns them.

Every day, new opportunities emerge around M&A and we help professionals of all types comb through transactions, investors, and corporate acquirers via an easy-to-use web database that is accessible to anyone.

Try us for 1 week free today!

Mergr, the Easiest-to-Use PE and M&A DB

Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 4.6K Private Equity Firms
  • 194K M&A Transactions
  • 198K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 3.6K M&A Advisors
    (Investment Banks and Law Firms)
  • 75K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.

Related Lists for iBio - Preclinical PD-1 Agonist Antibody Program

Texas Companies , Life Science Companies , United States Companies , Texas Life Science Companies , Texas Life Science with Acquisitions , Texas Life Science with Divestitures

Related Lists for Texas Companies

Largest Texas Companies , Acquisitive Texas Companies , Recently Acquired Texas Companies , Recently Sold Texas Companies , Private Texas Companies , Public Texas Companies , Acquired Texas Companies , PE Backed Texas Companies

Related Lists for Life Science Companies

Largest Life Science Companies , Acquisitive Life Science Companies , Recently Acquired Life Science Companies , Recently Sold Life Science Companies , Private Life Science Companies , Public Life Science Companies , Acquired Life Science Companies , PE Backed Life Science Companies

Related Lists for United States Companies

Largest United States Companies , Acquisitive United States Companies , Recently Acquired United States Companies , Recently Sold United States Companies , Private United States Companies , Public United States Companies , Acquired United States Companies , PE Backed United States Companies
Mergr

Product

Company

Legal